RxDoctor Payments Data

Kushagra Maini, MD

Neurology · Little River, SCNPI 1932620259

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (49.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 69.0% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2021 at $7,510 and has fallen 98.4% since, to $122 in 2025.

$14,945in general payments, 2019–2025

Across 163 payments — averaging $91.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$10K
  • Abbott$3K
  • Nevro Corp.$253
  • Inari Medical, Inc.$196
  • Teva Pharmaceuticals USA, Inc.$189
  • Avanos Medical$133
  • plus $1K from 28 others

What the payments were for

  • Grants$7,41850%
  • Travel & lodging$2,76418%
  • Food & beverage$4,76332%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,945 in reported general payments places this provider in the 80th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$205,956
Medicare patients
504
Services billed
36,685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GlatopaGlatiramer Acetate11$27,100
Nurtec OdtRimegepant Sulfate19$26,625
Lidocaine80$11,331
Pregabalin275$4,906
Gabapentin383$4,331
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen378$4,034
Duloxetine Hcl215$3,973
Diclofenac Sodium250$3,135
Tizanidine Hcl466$2,831
Celecoxib128$2,619
Dimethyl Fumarate12$1,213
Memantine Hcl44$1,203
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen60$993
Oxycodone Hcl61$945
Desonide13$893

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$51$26,62519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 270 neurology providers in South Carolina.

Other neurology in Little River

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →